Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

NCT03567499 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The decision to end the study was made for GSK portfolio reasons. No subjects were randomised into the study.

Conditions

Amyloidosis

Interventions

DRUG: GSK3039294
DRUG: Placebo

Sponsor

GlaxoSmithKline